î
îŒ
ãã°ã€ã³
î
Purple Biotech Ltd
PPBT4.100USD
+0.110+2.76%
ååŒæé ïŒETïŒ15åé
ãã®æ ªäŸ¡
3.81Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Purple Biotech Ltd äŒæ¥å
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Purple Biotech Ltdã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãPPBT
äŒç€ŸåPurple Biotech Ltd
äžå Žæ¥Sep 03, 1978
æé«çµå¶è²¬ä»»è
ãCEOãEfron (Gil)
åŸæ¥å¡æ°9
蚌åžçš®é¡Depository Receipt
決ç®ææ«Sep 03
æ¬ç€Ÿæåšå°4 Oppenheimer St.
éœåžREHOVOT
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIsrael
éµäŸ¿çªå·7670104
é»è©±çªå·97239333121
ãŠã§ããµã€ãhttps://purple-biotech.com/
äŒæ¥ã³ãŒãPPBT
äžå Žæ¥Sep 03, 1978
æé«çµå¶è²¬ä»»è
ãCEOãEfron (Gil)
Purple Biotech Ltdã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
Mr. Simcha Rock
Mr. Simcha Rock
Director
Director
--
--
Dr. Gil Ben-Menachem
Dr. Gil Ben-Menachem
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Ido Agmon
Mr. Ido Agmon
Independent Director
Independent Director
--
--
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
Mr. Arie Weber
Mr. Arie Weber
Independent Director
Independent Director
--
--
Ms. Revital Stern-Raff
Ms. Revital Stern-Raff
Independent Director
Independent Director
--
--
Mr. Ran Tzror
Mr. Ran Tzror
Independent Director
Independent Director
--
--
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
General Counsel, Secretary
General Counsel, Secretary
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
Mr. Simcha Rock
Mr. Simcha Rock
Director
Director
--
--
Dr. Gil Ben-Menachem
Dr. Gil Ben-Menachem
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Ido Agmon
Mr. Ido Agmon
Independent Director
Independent Director
--
--
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Wed, Feb 25
æŽæ°æå»: Wed, Feb 25
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Lincoln Alternative Strategies LLC
6.51%
Susquehanna International Group, LLP
5.06%
Orca Capital GmbH
3.30%
Two Sigma Investments, LP
1.83%
SmartHarvest Portfolios, LLC
0.51%
ä»ã®
82.80%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Lincoln Alternative Strategies LLC
6.51%
Susquehanna International Group, LLP
5.06%
Orca Capital GmbH
3.30%
Two Sigma Investments, LP
1.83%
SmartHarvest Portfolios, LLC
0.51%
ä»ã®
82.80%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
8.98%
Corporation
6.51%
Hedge Fund
2.29%
Research Firm
0.40%
Investment Advisor/Hedge Fund
0.03%
ä»ã®
81.79%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Thu, Jan 1
æŽæ°æå»: Thu, Jan 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
37
426.85K
4.59%
+179.93K
2025Q3
40
355.08K
3.82%
+98.77K
2025Q2
37
55.19K
1.82%
-201.60K
2025Q1
39
103.31K
6.70%
-153.87K
2024Q4
41
133.07K
5.02%
-58.34K
2024Q3
39
222.98K
11.78%
+111.64K
2024Q2
39
147.98K
8.71%
+1.90K
2024Q1
40
184.47K
11.90%
+40.99K
2023Q4
40
174.27K
11.63%
+106.33K
2023Q3
38
64.91K
3.14%
-5.47K
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Lincoln Alternative Strategies LLC
605.00K
6.51%
+605.00K
--
Sep 04, 2025
Orca Capital GmbH
306.39K
3.3%
+306.39K
--
Sep 07, 2025
Citadel Advisors LLC
41.26K
0.44%
+41.26K
--
Sep 30, 2025
BNP Paribas Securities Corp. North America
11.28K
0.12%
+5.00K
+79.68%
Sep 30, 2025
Simplex Trading, LLC
157.00
0%
+104.00
+196.23%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
1.08K
0.01%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
11.06K
0.12%
+6.50K
+142.39%
Sep 30, 2025
詳现ãèŠã
é¢é£ETF
îéæå
æ¯ç
ããŒã¿ãªã
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Feb 10, 2026
Merger
10â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Aug 13, 2020
Merger
10â1
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Feb 10, 2026
Merger
10â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Aug 13, 2020
Merger
10â1
Aug 13, 2020
Merger
10â1
Aug 13, 2020
Merger
10â1
Aug 13, 2020
Merger
10â1
